CureDuchenne Webinar with Edgewise Therapeutics: A Novel Approach to Protect Muscle in Duchenne

Join Edgewise’s Chief Scientific Officer and Chief Medical Officer to discuss the clinical development program for EDG-5506, a myosin modulator, that aims to prevent muscle damage in Becker and Duchenne muscular dystrophies. The webinar will highlight the mechanism of action, results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy, and currently recruiting trails in Duchenne and Becker.

Recorded Wednesday, March 29, 2023